In summary, our study has shown that GGQLD can effectively treat asymptomatic hyperuricemia (HUA) patients by modulating the expression of circadian clock genes and regulating the proportion of ILC cells, as supported by our clinical data and in vitro experiments. The gene discussed is CLOCK; the disease is hyperuricemia.